Kusajili – Clinical trials directory

Result of your search per sponsor: MedImmune, Ltd, a wholly owned subsidiary of AstraZeneca UK

Woman and Man Max 99 years
MedImmune, Ltd, a wholly owned subsidiary of AstraZeneca UK Update Il y a 4 ans

A Phase 2B study of multiple doses to evaluate the safety and treatment benefits of MEDI2070 in subjects with Crohn's Disease who have failed or are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy The primary objective of this study is to evaluate the efficacy of MEDI2070 versus placebo to induce clinical remission based on the CDAI score at Week 8 in subjects with moderate to severe CD who hav...

Country None
organs None
Specialty None

unknown

More information